Dosimetric and radiobiological impact of intensity modulated proton therapy and RapidArc planning for high‐risk prostate cancer with seminal vesicles

Rana, Suresh; Cheng, Catherine; Zhao, Li; Park, SungYong; Larson, Gary; Vargas, Carlos; Dunn, Megan; Zheng, Yuanshui

doi:10.1002/jmrs.175

Cited by 15 publications

(8 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The PTV volume is enlarged by prostate hypertrophy and T3b disease, thus affecting the rectal dose. PBT is known to deliver a lower dose to the rectum and bladder, particularly in high-risk cases where seminal vesicle irradiation is required ( 32 , 33 ), which supports the results of the present study.…”

Section: Discussionsupporting

confidence: 91%

A retrospective study of late adverse events in proton beam therapy for prostate cancer

Makishima

Ishikawa

Tanaka

et al. 2017

Molecular and Clinical Oncology

View full text Add to dashboard Cite

The efficacy and safety of proton beam therapy (PBT) were retrospectively evaluated in 111 consecutive patients with prostate cancer who underwent definitive PBT between 2008 and 2012. Following exclusion of 18 patients due to treatment suspension, loss to follow-up, and histology, the analysis included 93 patients with a median age of 68 years (range, 49–81 years). A total of 7, 32 and 54 prostate cancer patients were classified as low-, intermediate- and high-risk, respectively, as follows: High-risk, T≥3a or prostate-specific antigen (PSA) ≥20 ng/ml or Gleason Score ≥8; low-risk, T ≤2b and PSA≤10 ng/ml and Gleason Score=6; intermediate-risk, all other combinations. The median initial prostate-specific antigen (PSA) level was 9.75 ng/ml (range, 1.4–100 ng/ml) and the median Gleason score was 7 (range, 6–10). Patients with low-risk disease received 74 GyE (relative biological effectiveness=1.1) in 37 fractions, and those at intermediate or higher risk received 78 GyE in 39 fractions. Complete androgen blockade (CAB) therapy was performed from 6 months prior to PBT for patients with intermediate- or high-risk disease. CAB was continued during PBT and then terminated at the end of PBT for intermediate-risk patients. Patients at high risk continued CAB for 3 years. No combination therapy was used for low-risk patients. All the patients were followed up for >2 years after PBT, and all but one were PSA failure-free. The Common Terminology Criteria for Adverse Events v.4.0 was used to evaluate late adverse events. One patient developed grade 3 non-infectious cystitis and hematuria. Grade 2 urinary frequency was observed in 1 patient, and grade 2 rectal bleeding occurred in 4 patients. Of the 4 patients with grade 2 rectal bleeding, 2 received anticoagulant therapy, but none had diabetes mellitus or another high-risk comorbidity. The median time to occurrence of an adverse event of grade ≥2 was 14 months (range, 3–41 months). Therefore, the present retrospective study revealed that PBT at 78 GyE/39 Fr was well-tolerated and achieved good tumor control in patients with prostate cancer.

show abstract

Section: Discussionsupporting

confidence: 91%

A retrospective study of late adverse events in proton beam therapy for prostate cancer

Makishima

Ishikawa

Tanaka

et al. 2017

Molecular and Clinical Oncology

View full text Add to dashboard Cite

show abstract

“…[ 31 32 ] Many studies have suggested that radiobiological modeling that can instantly represent local tumor control and normal tissue complications is a key factor in choosing the optimal radiotherapy technique. [ 33 34 35 ]…”

Section: Discussionmentioning

confidence: 99%

Pediatric Craniospinal Irradiation – The implementation and Use of Normal Tissue Complication Probability in Comparing Photon versus Proton Planning

Shobana¹,

Balasubramanian²

2021

Journal of Medical Physics

View full text Add to dashboard Cite

Purpose: The preferred radiotherapy treatment for medulloblastoma is craniospinal irradiation (CSI). With the aim of developing the potential to reduce normal tissue dose and associated post-treatment complications with photon and proton radiotherapy techniques for CSI. This report aims to carefully compare and rank treatment planning and dosimetric outcomes for pediatric medulloblastoma patients using normal tissue complication probability (NTCP) formalism between photon (three-dimensional conformal radiotherapy, intensity-modulated radiotherapy [IMRT], volumetric-modulated arc therapy [VMAT], and HT) and proton CSI. Methods and Materials: The treatment data of eight pediatric patients who typically received CSI treatment were used in this study. The patients were 7 years of age on average, with ages ranging from 3 to 11 years. A prescription dose of 3600 cGy was delivered in 20 fractions by the established planning methods. The Niemierko's and Lyman–Kutcher–Burman models were followed to carefully estimate NTCP and compare different treatment plans. Results: The NTCP of VMAT plans in upper and middle thoracic volumes was relatively high compared to helical tomotherapy (HT) and pencil beam scanning (PBS) (all P < 0.05). PBS rather than IMRT and VMAT in the middle thoracic region ( P < 0.06) could significantly reduce the NTCP of the heart. PBS significantly reduced NTCP of the lungs and liver (all P < 0.05). Conclusion: The NTCP and tumor control probability (TCP) model-based plan ranking along with dosimetric indices will help the clinical practitioner or medical physicists to choose the best treatment plan for each patient based on their anatomical or clinical challenges.

show abstract

“…The 𝑎 value is typically chosen to be negative value for the tumour. In the case of prostate cancer, the value 𝑎 = −10 is used [16,10]. From the general point The TCP can be calculated based on the EUD value [11,12]:…”

Section: Methodsmentioning

confidence: 99%

Estimation of treatment efficiency of head-and-neck cancer based on tumour control probability model

Sergeevna¹,

Grigorievich²,

Nikolaevna³

et al. 2023

S. F. J. of Dev.

View full text Add to dashboard Cite

External beam radiotherapy is widely used for the treatment of the locally advanced head-and-neck cancer (LAHNC). Analysis of the developed treatment plans based on tumour control probability (TCP) models could help to estimate expected treatment results of the developed plans and to find optimal treatment schemes with respect to total dose, fractional dose and overall treatment time (OTT). In this study, the simultaneous integrated boost VMAT (SIB-VMAT) plans and sequential boost VMAT (SEQ-VMAT) plans were developed based on the anatomical data of 11 patients. Methods and Material: The data of 11 patients with LAHNC (larynx, oropharynx and oral cavity) were used. For each patient two treatment plans were developed, SIB-VMAT (70 Gy to tumour, 50 Gy to lymph nodes, 25 fractions) and SEQ-VMAT (70 Gy to tumour, 50 Gy to lymph nodes, 35 fractions). The developed plans were analysed using the Niemierko’s TCP model with Maciejewski’s parameters (TCD50 = 70.26 Gy at 49-days OTT) taking into account dose-volume histograms and OTT. Results: The developed plans resulted in high clinical treatment volume (CTV) conformity (98%-98%) for all patients, except one. The average TCP value of SIB-VMAT was equal to 99.9% due to very short OTT. The average value of TCP for SEQ-VMAT was equal to 61.0%. For one patient, the both SIB-VMAT and SEQ-VMAT plans showed zero expected efficiency due to CTV coverage 95%-95%. Conclusions: Use of TCP models allows analysis of treatment plans for each particular patient and development of different treatment schemes with increase of the total dose value, fractional dose and shortening of OTT.

show abstract

Dosimetric and radiobiological impact of intensity modulated proton therapy and RapidArc planning for high‐risk prostate cancer with seminal vesicles

Cited by 15 publications

References 26 publications

A retrospective study of late adverse events in proton beam therapy for prostate cancer

A retrospective study of late adverse events in proton beam therapy for prostate cancer

Pediatric Craniospinal Irradiation – The implementation and Use of Normal Tissue Complication Probability in Comparing Photon versus Proton Planning

Estimation of treatment efficiency of head-and-neck cancer based on tumour control probability model

Contact Info

Product

Resources

About